Anti-IL-6R (Tocilizumab biosimilar) antibody family
Product | Unit size | Cat. code | Docs. | Qty. | Price | |
---|---|---|---|---|---|---|
Anti-hIL6R-To-hIgG1 Human IL-6R (Tocilizumab) antibody - Human IgG1 |
Show product |
100 µg 1 mg |
hil6rto-mab1
|
|
||
Anti-hIL6R-To-hIgG1NQ Human IL-6R (Tocilizumab) antibody - Human IgG1NQ |
Show product |
100 µg 3 x 100 µg |
hil6rto-mab12
|
|
||
Anti-hIL6R-To-hIgA2 Human IL-6R (Tocilizumab) antibody - Human IgA2 |
Show product |
100 µg 3 x 100 µg |
hil6rto-mab7
|
|
Human monoclonal antibody (mAb) isotypes against human IL-6R
Tocilizumab blocks IL-6R signaling
InvivoGen provides a family of anti-hIL6R-derived monoclonal antibodies (mAbs) in multiple human isotypes. These mAbs feature:
- the variable region of tocilizumab, which specifically targets the human interleukin-6 receptor (hIL6R)
- a constant region that mediates different effector functions depending on the isotype: hIgG1, hIgG1NQ or IgA2
The Anti-hIL6R-To-hIgG1 mAb is the biosimilar of the clinical antibody tocilizumab. InvivoGen's hIL6R mAbs have been generated by recombinant DNA technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography.
IL-6R background
Tocilizumab (TCZ) is a recombinant, humanized monoclonal antibody (mAb) directed against both soluble and membrane-bound human IL-6R. TCZ exhibits anti-inflammatory activity by inhibiting the binding of the pro-inflammatory cytokine, IL-6 to its receptor [1]. IL-6 exerts its biological effects through IL-6R, and the transmembrane protein gp130. Despite only a few cells expressing IL-6R on their surface, many cells respond to IL-6 due to the existence of soluble IL-6R [2]. TCZ can block both modes of signaling [1]. TCZ has been approved for the treatment of inflammatory diseases and conditions such as rheumatoid arthritis (RA) and cytokine release syndrome (CRS), a side effect of CAR-T therapy. Furthermore, it is under investigation for the treatment of the late-stage hyperinflammation observed in severe COVID‑19 patients [3].
Key features of the Anti-hIL6R isotype family:
- Clinically-relevant variable region targeting human IL-6R (Tocilizumab).
- Inhibition of IL-6-dependent signaling by Anti-hIL6R-To mAbs has been validated in HEK-Blue™ IL-6 cellular assays.
- The absence of bacterial contamination has been confirmed.
InvivoGen’s products are for research use only, and not for clinical or veterinary use.
COVID-19 related research
Severe COVID-19 patients have been shown to exhibit high levels of pro-inflammatory cytokines, such as IL-6, which can ultimately initiate life-threatening hyper-inflammation and a “cytokine storm” in the lungs and other organs. Tocilizumab is being explored as a potential therapeutic in the treatment of these patients.
Read our reviews on COVID-19 and learn more about SARS-CoV-2 infection cycle, immune responses, and potential therapeutics.
References:
1. Sheppard, M. et al. 2017. Tocilizumab (Actemra). Hum Vaccin Immunother 13, 1972- 1988.
2. Rose-John, S. 2012. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8, 1237-1247.
3. Zhang, S. et al. 2020. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig.
Specifications
Specificity: Human Interleukin-6 receptor (hIL-6R)
Clonality: Monoclonal antibodies
Clone: Tocilizumab (Anti-hIL-6R-hIgG1, kappa)
Control: Human IgG1, hIG1NQ, hIgA2
Source: CHO cells
Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents.
Tested application: Functional assay
Purification:
- hIgG1: purified by affinity chromatography with protein G
- hIgG1NQ: purified by affinity chromatography with protein G
- hIgA2: purified by affinity chromatography with peptide M
Quality control:
- The complete sequence of each antibody construct has been verified.
- Each antibody has been functionally validated using HEK-Blue™ IL-6 cellular assays
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.
Contents
Please note: Each product is sold separately. These purified monoclonal antibodies are provided azide-free and lyophilized.
Anti-hIL6R-To-hIgG1 is available in two quantities:
- hil6rto-mab1: 100 µg
- hil6rto-mab1-1: 1 mg
Anti-hIL6R-To-hIgG1NQ is available in two quantities:
- hil6rto-mab12: 100 µg
- hil6rto-mab12-03: 3 x 100 µg
Anti-hIL6R-To-hIgA2 is available in two quantities:
- hil6rto-mab7: 100 µg
- hil6rto-mab7-03: 3 x 100 µg
The product is shipped at room temperature.
Upon receipt, store at -20°C.
Tags: buy Tocilizumab (anti-IL-6R) | Tocilizumab (anti-IL-6R) supplier | purchase Tocilizumab (anti-IL-6R) | Tocilizumab (anti-IL-6R) cost | Tocilizumab (anti-IL-6R) manufacturer | order Tocilizumab (anti-IL-6R) | Tocilizumab (anti-IL-6R) distributor
Back to the top